Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four chemotherapeutic agents with different mechanisms of action. Docetaxel is a taxane that inhibits microtubule disassembly. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Paclitaxel is another taxane that stabilizes microtubules. Pemetrexed is a folate analog that inhibits multiple enzymes involved in folate metabolism and DNA synthesis. Each of these drugs has established efficacy in various cancers, particularly non-small cell lung cancer (NSCLC). While these drugs have been studied in various two-drug combinations, there is limited information about all four being used together as a single regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docetaxel + gemcitabine + paclitaxel + pemetrexed.